Modality
Small Molecule
MOA
GLP-1ag
Target
CD3
Pathway
JAK/STAT
WilmsCKDMCL
Development Pipeline
Preclinical
Nov 2020
→ Sep 2031
PreclinicalCurrent
NCT04493536
1,574 pts·CKD
2020-11→2031-09·Completed
1,574 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-145.5y awayInterim· CKD
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2031-09-14 · 5.5y away
CKD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04493536 | Preclinical | CKD | Completed | 1574 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 |